-
-
-
-
-
-
-
Takeda's TAK-881 meets primary endpoint in Phase 2/3 PID trial
-
-
-
-
-
-
-
FDA accepts Takeda's zasocitinib drug application for plaque psoriasis
-
-
-
-
-
-
-
FDA approves Takeda's Orzeyful for narcolepsy type 1 in adults
-
-
-
-
-
-
-
Takeda Announces New Assignments of Directors and Appointment of Julie Kim as Representative Director, President and CEO
-
-
-
-
-
-
-
Takeda Announces FY2025 Full Year Results and FY2026 Outlook, Highlighted by Excellent Pipeline Progress and Solid FY2025 Results
-
-
-
-
-
-
-
Takeda reports positive pediatric trial results for ENTYVIO ulcerative colitis treatment
-
-
-
-
-
-
-
Oncolytics Biotech® Appoints John McAdory as EVP of Strategy and Operations and Yujun Wu to Lead Biostatistics
-
1,202,202 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


